Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. META
2. DAL
3. NFLX
4. IONS
5. FRMI
6. MSA
7. CANG
8. R
9. EAND
10. SKHY

Go back to Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Pa
(NASDAQ: VRCA) Delayed: 6.53 --0 (-0%)
Previous Close $6.53    52 Week High $ 
Open $6.53    52 Week Low $ 
Day High $6.53    P/E N/A 
Day Low $6.53    EPS $ 
Volume 13